Saturday 17 October 2026
Export PYXS’s income statement to Excel — free account
Pyxis Oncology, Inc.
PYXS Healthcare Biotechnology
Pyxis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.9 million, down 14.2% from fiscal 2024. In the quarter to June 2026, EPS fell 33.3% and free cash flow fell 5.46%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.68
0.12
−6.67%
Follow PYXS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(87.28%) | (91.43%) | (121.66%) | (179.10%) | |
| (64.53%) | (64.03%) | (81.67%) | (99.62%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(134.56%) | (135.02%) | (223.45%) | (537.84%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.16) | (1.02) | (1.06) | (1.06) | |
Free Cash Flow |
(72.37) | (63.51) | (66.97) | (67.91) | |
Capital Expenditures |
(0.01) | (0.01) | — | — | |
| Other line items | |||||
Cash ROIC |
(49.40%) | (52.17%) | (90.79%) | (147.93%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.02 | 0.02 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.75 | 0.80 | 0.82 | 0.77 | |
Depreciation/Fixed assets |
(0.23) | 0.19 | 0.32 | 0.39 | |
Capex/Depreciation |
0.00 | (0.01) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.16) | (1.02) | (1.06) | (1.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates